Meeting
2018 ASCO Annual Meeting
Integrated clinical experience with ONC201 in H3 K27M glioma.
Authors
Andrew S. Chi
Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA
Andrew S. Chi , Sharon L. Gardner , Isabel Arrillaga , Patrick Y. Wen , Tracy Batchelor , Matthew David Hall , Yazmin Odia , Wafik Tharwat Zaky , Soumen Khatua , Nicole A. Shonka , Ziad Khatib , Rohinton Tarapore , Lee Schalop , Joshua E. Allen , Wolfgang Oster , Minesh P. Mehta
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT03295396, NCT02525692, NCT03416530
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2059)
DOI
10.1200/JCO.2018.36.15_suppl.2059
Abstract #
2059
Poster Bd #
217
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma.
First Author: Sylvia Christine Kurz
Poster
2020 ASCO Virtual Scientific Program
Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.
First Author: Isabel Arrillaga-Romany
Poster
2020 ASCO Virtual Scientific Program
ONC201 in previously irradiated pediatric H3 K27M-mutant glioma or newly diagnosed DIPG.
First Author: Sharon L. Gardner
Poster
2022 ASCO Annual Meeting
Window-of-opportunity study of ONC201 in pediatric patients with diffuse intrinsic pontine glioma (DIPG) and thalamic glioma.
First Author: Yazmin Odia